PharmaRoth Labs, Inc. (ROTH)

[old biohf guy]

sweetlou, thanks for your excellent explanation on these two points.

My 2 cents says that Tianjin is old news and didn't pan out, and Renuen is irrelavent. These are both side issues and everyone should be focused on what is happening today and tomorrow concerning Roth. Looking back at these 2 side issues is like driving and focusing on the rearview mirror.

Looking ahead out the front windshield, in plain view, is completion of the 12 week clinical trials, approval by the Indian government, and then Indian sales through Canagen.

Remember in life, as in stocks, it is sometimes more important the direction you are going than where you have been.